zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2009-6-3-1zdor-842Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEКЛИНИКО-ФАРМАКОЛОГИЧЕСКАЯ ХАРАКТЕРИСТИКА БЛОКАТОРОВ РЕЦЕПТОРОВ АНГИОТЕНЗИНА II В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ И ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИClinical and pharmacologic characteristic of Angiotensin II Receptor Blockers in the treatment of arterial hypertension and chronic heart failureБронскаяГ. М.BronskayaG. M.noemail@neicon.ruКоршакТ. А.KorshakT. A.noemail@neicon.ruКазакевичД. В.KazakevichD. V.noemail@neicon.ruГомельский государственный медицинский университетGomel State Medical UniversityГродненский государственный медицинский университетGrodno State Medical University20092809200903711Copyright © Бронская Г.М., Коршак Т.А., Казакевич Д.В., 20092009Бронская Г.М., Коршак Т.А., Казакевич Д.В.Bronskaya G.M., Korshak T.A., Kazakevich D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/842

Обзор посвящен блокаторам ангиотензиновых рецепторов (AT1 блокаторы, БАТ, сартаны) и их общим свойствам и особенностям. Для этого рассмотрено их влияние на рецепторы, фармакокинетика и показания к применению. Кроме того, уделено внимание индивидуальным особенностям БАТ, применяющимся в настоящее время.

A survey is presented of the angiotensin II receptor antagonists (AT1 blockers, sartans) and their general properties and similarities. Accordingly, their receptor profile, pharmacokinetic and therapeutic applications are discussed. In addition, attention is paid to the individual characteristics of the AT1 blockers now available.

ртериальная гипертензияблокаторы ангиотензиновых рецепторовфармакологические свойстваarterial hypertensionangiotensin II receptor antagonistspharmacological propertiesReferencesAngiotensin receptors and their antagonists / T.L. Goodfriend [et al.] // N Engl J Med. - 1996. - Vol. 334. - P. 1649-1654.Angiotensin receptors and their antagonists / T.L. Goodfriend [et al.] // N Engl J Med. - 1996. - Vol. 334. - P. 1649-1654.Tarascon Pocket Pharmacopoeia. - Loma Linda, 2006. - P. 86.Tarascon Pocket Pharmacopoeia. - Loma Linda, 2006. - P. 86.Остроумова, О. Д. Антагонисты рецепторов ангиотензина II / В. Г. Кукес [и др.] // Клиническая фармакология: учеб. / В. Г. Кукес. - 3-е изд., испр. и доп. - М., 2004. - С. 297-300.Остроумова, О. Д. Антагонисты рецепторов ангиотензина II / В. Г. Кукес [и др.] // Клиническая фармакология: учеб. / В. Г. Кукес. - 3-е изд., испр. и доп. - М., 2004. - С. 297-300.Moser, M. Clinical Management of Hypertension / M. Moser. - 2nd ed. - PCI, 997. - 192 р.Moser, M. Clinical Management of Hypertension / M. Moser. - 2nd ed. - PCI, 997. - 192 р.The Seventh Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure // JAMA. - 2003. - Vol. 289. - P. 2560-2571.The Seventh Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure // JAMA. - 2003. - Vol. 289. - P. 2560-2571.Morrison, A. E. Hypertension / A. E. Morrison // The Washington Manual™ of Medical Therapeutics / G. B. Green [et al.]. - 31st ed. - Lippincott Williams & Wilkins, 2004. - P. 72-92.Morrison, A. E. Hypertension / A. E. Morrison // The Washington Manual™ of Medical Therapeutics / G. B. Green [et al.]. - 31st ed. - Lippincott Williams & Wilkins, 2004. - P. 72-92.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against Atenolol / B. Dahlof [et al.] // Lancet. - 2002. - Vol. 359. - P. 995-1003.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against Atenolol / B. Dahlof [et al.] // Lancet. - 2002. - Vol. 359. - P. 995-1003.RENAAL-study investigations. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy / B. M. Brenner [et al.] // N Engl J Med. - 2001. - Vol. - 345. - P. 861-869.RENAAL-study investigations. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy / B. M. Brenner [et al.] // N Engl J Med. - 2001. - Vol. - 345. - P. 861-869.Pitt, B. On behalf of the ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly Study, ELITE) / B. Pitt [et al] // Lancet. - 1997. - Vol.349. - P. 747-752.Pitt, B. On behalf of the ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly Study, ELITE) / B. Pitt [et al] // Lancet. - 1997. - Vol.349. - P. 747-752.Burnier, M. Angiotensin II type 1 receptor blockers / M. Burnier // Circulation. - 2001. - Vol. 103. - P. 904-912.Burnier, M. Angiotensin II type 1 receptor blockers / M. Burnier // Circulation. - 2001. - Vol. 103. - P. 904-912.The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double blind intervention trial / H. Lithell [et al.]// J Hypertens. - 2003. - Vol. 21. - P. 875-886.The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double blind intervention trial / H. Lithell [et al.]// J Hypertens. - 2003. - Vol. 21. - P. 875-886.White, H. D. Candesartan and heart failure: the allure of CHARM / H. D. White //Lancet. - 2003. - Vol. 362. - P. 754-755.White, H. D. Candesartan and heart failure: the allure of CHARM / H. D. White //Lancet. - 2003. - Vol. 362. - P. 754-755.McCellan, K. J. Eprosartan / R. J. McCellan, J. A. Balfour // Drugs. - 1998. - Vol. 55. - P. 713-718.McCellan, K. J. Eprosartan / R. J. McCellan, J. A. Balfour // Drugs. - 1998. - Vol. 55. - P. 713-718.Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes / E. J. Lewis [et al.] // N EnglJ Med. - 2001. - Vol. 345. - P. 851-860.Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes / E. J. Lewis [et al.] // N EnglJ Med. - 2001. - Vol. 345. - P. 851-860.Gillis, J. C. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension / J. C. Gillis, A. Markham // Drugs. - 1997. - Vol. 54. - P. 885-902.Gillis, J. C. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension / J. C. Gillis, A. Markham // Drugs. - 1997. - Vol. 54. - P. 885-902.Brunner, H. R. Clinical efficacy of olmesartan medoxomil / H. R. Brunner, P. Laers // J Hypertens. - 2003. - Vol. 21 (Suppl 2). - P. 543-546.Brunner, H. R. Clinical efficacy of olmesartan medoxomil / H. R. Brunner, P. Laers // J Hypertens. - 2003. - Vol. 21 (Suppl 2). - P. 543-546.Unger, T. The role of olmesartan medoxomil in the management of hypertension / T. Unger [et al.] // Drugs. - 2004. - Vol. 64. - P. 2731-2739.Unger, T. The role of olmesartan medoxomil in the management of hypertension / T. Unger [et al.] // Drugs. - 2004. - Vol. 64. - P. 2731-2739.Angiotensin receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy / A. H. Barnett [et al.] // N Engl J Med. - 2004. - Vol. 351. - P. 1952-1961.Angiotensin receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy / A. H. Barnett [et al.] // N Engl J Med. - 2004. - Vol. 351. - P. 1952-1961.Angiotensin type I receptor include peroxizome proliferator activated receptoryactivity / M. Schupp [et al.] // Circulation. - 2004. - Vol. 109. - P. 2054-2057.Angiotensin type I receptor include peroxizome proliferator activated receptoryactivity / M. Schupp [et al.] // Circulation. - 2004. - Vol. 109. - P. 2054-2057.Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan / S. G. Chrysants [et al.] // J Hum Hypertens. - 2005. - Vol. 19. - P. 173-183.Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan / S. G. Chrysants [et al.] // J Hum Hypertens. - 2005. - Vol. 19. - P. 173-183.VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimes based on valsartan or amlodipine: the VALUE randomized trial S. Julius [et al.] // Lancet. - 2004. - Vol. 363. - P. 2022-2031.VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimes based on valsartan or amlodipine: the VALUE randomized trial S. Julius [et al.] // Lancet. - 2004. - Vol. 363. - P. 2022-2031.Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both / M. A. Pfeffer [et al.] // N Engl J Med. - 2003. - Vol. 349. - P. 1893-1906.Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both / M. A. Pfeffer [et al.] // N Engl J Med. - 2003. - Vol. 349. - P. 1893-1906.Viberti, G.C. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure independent effect / G. C. Viberti, M. N. Wheeldon // Circulation. - 2002. - Vol. 106. - P. 672-678.Viberti, G.C. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure independent effect / G. C. Viberti, M. N. Wheeldon // Circulation. - 2002. - Vol. 106. - P. 672-678.

The authors declare that there are no conflicts of interest present.